Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

STORM Therapeutics

STORM Therapeutics
2015 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$38.8M LATEST DEAL AMOUNT
8 INVESTORS
Description

Developer of small molecule drugs designed to develop first-in-class drugs in oncology and other diseases. The company's small molecule drugs tackles diseases through modulating RNA modifying enzymes and develops a platform to address these enzyme classes, including RNA non transferable, enabling physicians to access RNA-modifying enzymes for the treatment of cancer.

Formerly Known As
Iceni Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Babraham Research Campus
  • Moneta Building
  • Cambridge CB22 3AT
  • England, United Kingdom

+44 01223 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore STORM Therapeutics’s full profile, request a free trial.

STORM Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 20-May-2019 $38.8M 000.00 Completed Generating Revenue
2. Early Stage VC 07-May-2015 00000 00.000 Completed Generating Revenue
1. Seed Round 01-May-2015 $748K $748K Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

STORM Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

STORM Therapeutics Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytImmune Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 000.00 00000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
000 000000000000 Venture Capital-Backed Boston, MA 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

STORM Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cambridge Enterprise Venture Capital Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
Seroba Life Sciences Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

STORM Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Keith Blundy Ph.D Chief Executive Officer & Board Member
Tony Kouzarides Ph.D Board Member & Co-Founder
Eric Miska Ph.D Co-Founder & Board Member
Wesley Blackaby Ph.D Vice President Chemistry
Oliver Rausch Ph.D Vice President, Research & Development

STORM Therapeutics Board Members (13)

Name Representing Role Since Contact
Info
Bradley Hardiman Cambridge Enterprise Board Observer 000 0000
Christine Martin Cambridge Enterprise Board Member & Board Observer 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Member 000 0000
Eric Miska Ph.D STORM Therapeutics Co-Founder & Board Member 000 0000
Hakan Goker Ph.D M Ventures Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 13 board members. Get the full list »